Natco Pharma announced its financial results for the second quarter and half year ended September 30, 2026. The Board of Directors declared an interim dividend of ₹1.25 per equity share. Consolidated revenue stood at ₹1,019.4 crore for the quarter, with profit after tax of ₹202.6 crore. The record date for the dividend payment is set as November 19, 2026, with payments commencing from November 27, 2026.
| Particulars | Quarter Ended 30-09-2026 | Quarter Ended 30-06-2026 | Quarter Ended 30-09-2025 | Half Year Ended 30-09-2026 | Half Year Ended 30-09-2025 | Year Ended 31-03-2026 |
| Total Revenue (Consolidated) | ₹1,019.4 Crore | ₹794.4 Crore | ₹1,463.0 Crore | ₹1,813.8 Crore | ₹2,257.4 Crore | ₹40,783 Crore |
| Profit After Tax (Consolidated) | ₹202.6 Crore | ₹206.5 Crore | ₹517.9 Crore | ₹409.1 Crore | ₹724.4 Crore | ₹14,185 Crore |
| Earnings Per Share (INR) | ₹11.31 | ₹11.53 | ₹28.94 | ₹22.84 | ₹55.78 | ₹79.20 |
Dividend Declaration
The Board of Directors of Natco Pharma Limited has approved and declared a second interim dividend of ₹1.25 per equity share of face value ₹2 each for the financial year 2026-27. The record date for determining the shareholders eligible for this dividend has been fixed as Thursday, November 19, 2026. The dividend payments are scheduled to commence from November 27, 2026.
Financial Performance Highlights
Natco Pharma reported consolidated total revenue of ₹1,019.4 Crore for the quarter ended September 30, 2026, compared to ₹794.4 Crore in the previous quarter and ₹1,463.0 Crore in the corresponding quarter of the previous year. The profit for the period after share of profit of associate, on a consolidated basis, was ₹202.6 Crore, against ₹206.5 Crore in the prior quarter and ₹517.9 Crore in the same quarter last year. The company’s share of profit from its associate, Adcock Ingram Holdings Limited, contributed ₹29.2 Crore.
Segmental Performance
The segmental revenue breakdown for the quarter ended Q2FY27 shows:
- Active Pharmaceutical Ingredients (API): ₹61.3 Crore
- Domestic Pharmaceutical Formulations: ₹145.7 Crore
- International Formulations: ₹668.4 Crore
- Crop Health Sciences (CHS): ₹61.0 Crore
- Other operating and non-operating income: ₹83.0 Crore
The company also noted that its subsidiary, Adcock Ingram Holdings Limited, reported revenues of ₹1,343.8 Crores and a profit after tax of ₹80.5 Crores during the quarter. Natco Pharma acquired an additional 13.25% stake in Adcock Ingram, increasing its total holding to 49%.
Source: BSE
